{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:35:43Z","timestamp":1759970143685,"version":"build-2065373602"},"reference-count":64,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Coordination of Superior Level Staff Improvement (CAPES) (TBG and ACO fellowships)","award":["01.02.016301.04556\/2022-2","312807\/2022-8","315156\/2021-0"],"award-info":[{"award-number":["01.02.016301.04556\/2022-2","312807\/2022-8","315156\/2021-0"]}]},{"DOI":"10.13039\/501100004916","name":"FAPEAM","doi-asserted-by":"publisher","award":["01.02.016301.04556\/2022-2","312807\/2022-8","315156\/2021-0"],"award-info":[{"award-number":["01.02.016301.04556\/2022-2","312807\/2022-8","315156\/2021-0"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Council for Scientific and Technological Development (CNPq)","award":["01.02.016301.04556\/2022-2","312807\/2022-8","315156\/2021-0"],"award-info":[{"award-number":["01.02.016301.04556\/2022-2","312807\/2022-8","315156\/2021-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: Pharmacogenetics (PGx) aims to identify individuals more likely to suffer from adverse reactions or therapeutic failure in drug treatments. However, despite most of the evidence in this area being from European populations, some diseases have also been neglected, such as HIV infection, malaria, and tuberculosis. With this review, we aim to emphasize which pharmacogenetic tests are ready to be implemented in treating neglected diseases that have some evidence and call attention to what is missing for these three diseases. Methods: A critical literature review on the PGx of HIV infection, malaria, and tuberculosis was performed. Results: There are three PGx guidelines for antiretroviral drugs used in HIV infection, one for malaria, and none for tuberculosis. Some evidence is already available, and some genes have already been identified, such as CYP2D6 for primaquine treatment and NAT2 for isoniazid. However, some barriers to the implementation are the lack of evidence due to the few studies on the diseases themselves and the admixture of the most affected populations, which must be considered, given the genetic differentiation of these populations. Conclusions: PGx tests such as abacavir are already implemented in some places, and efavirenz\/atazanavir is ready to implement if this medication is used. Other gene\u2013drug associations were found but still do not present a clear recommendation. We call attention to the need to generate more evidence for testing treatments for other neglected diseases, such as malaria and tuberculosis, given their epidemiological importance and for the public health of less favored populations.<\/jats:p>","DOI":"10.3390\/genes16010054","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:17:02Z","timestamp":1736155022000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetics of the Treatment of Neglected Diseases"],"prefix":"10.3390","volume":"16","author":[{"given":"Tiffany Borges","family":"Cabral","sequence":"first","affiliation":[{"name":"Department of Pathology, Genetics and Evolution, Federal University of Tri\u00e2ngulo Mineiro, Uberaba 38025-180, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Carvalho","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Tropical Medicine, Amazonas State University (PPGMT\/UEA), Manaus 69040-000, Brazil"},{"name":"Tropical Medicine Foundation (FMT-HVD) Dr. Heitor Vieira Dourado, Manaus 69040-000, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisely Cardoso de","family":"Melo","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Tropical Medicine, Amazonas State University (PPGMT\/UEA), Manaus 69040-000, Brazil"},{"name":"Tropical Medicine Foundation (FMT-HVD) Dr. Heitor Vieira Dourado, Manaus 69040-000, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-3223","authenticated-orcid":false,"given":"Fernanda","family":"Rodrigues-Soares","sequence":"additional","affiliation":[{"name":"Department of Pathology, Genetics and Evolution, Federal University of Tri\u00e2ngulo Mineiro, Uberaba 38025-180, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,5]]},"reference":[{"key":"ref_1","unstructured":"de Souza, W. (2010). Doen\u00e7as Negligenciadas, Brazilian Academy of Sciences."},{"key":"ref_2","first-page":"515","article-title":"Farmacogen\u00e9tica: Princ\u00edpios, Aplica\u00e7\u00f5es e Perspectivas","volume":"39","author":"Metzger","year":"2006","journal-title":"Med. B Aires"},{"key":"ref_3","first-page":"38","article-title":"Cytochrome P450 Structure, Function and Clinical Significance: A Review","volume":"19","author":"Manikandan","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"VII","DOI":"10.1590\/s1679-45082017ed4016","article-title":"Precision Medicine","volume":"15","author":"Pinho","year":"2017","journal-title":"Einstein"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bcpt.13196","article-title":"Pharmacogenomics Research and Clinical Implementation in Brazil","volume":"124","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2042098612469335","article-title":"The ABCD of Clinical Pharmacokinetics","volume":"4","author":"Doogue","year":"2013","journal-title":"Ther. Adv. Drug. Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional Pharmacogenetics\/Genomics of Human Cytochromes P450 Involved in Drug Biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tornio, A., and Backman, J.T. (2018). Cytochrome P450 in Pharmacogenetics: An Update, Elsevier Inc.. [1st ed.].","DOI":"10.1016\/bs.apha.2018.04.007"},{"key":"ref_9","first-page":"85","article-title":"Farmacogen\u00e9tica Na Am\u00e9rica Latina","volume":"3","author":"Scudeler","year":"2020","journal-title":"Acta Biol. Bras."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2020588","DOI":"10.1590\/s1679-4974202100013.esp1","article-title":"Protocolo Brasileiro Para Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis 2020: Infec\u00e7\u00e3o Pelo HIV Em Adolescentes e Adultos","volume":"30","author":"Freitas","year":"2021","journal-title":"Epidemiol. Servi\u00e7os Sa\u00fade"},{"key":"ref_13","unstructured":"Departamento de HIV\/Aids, Tuberculose, Hepatites Virais e Infec\u00e7\u00f5es Sexualmente Transmiss\u00e9veis., Secretaria de Vigil\u00e2ncia em Sa\u00fade e Ambiente, and Minist\u00e9rio da Sa\u00fade (2023). Epidemiological Report\u2013HIV & AIDS 2023, Minist\u00e9rio da Sa\u00fade."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1590\/S0100-40422010000800023","article-title":"HIV: Mecanismo de Replica\u00e7\u00e3o, Alvos Farmacol\u00f3gicos e Inibi\u00e7\u00e3o Por Produtos Derivados de Plantas","volume":"33","author":"Ferreira","year":"2010","journal-title":"Quim. Nova"},{"key":"ref_15","unstructured":"(2024, September 17). Minist\u00e9rio da Sa\u00fade. Aids\/HIV, Available online: https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/a\/aids-hiv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV Infection: Epidemiology, Pathogenesis, Treatment, and Prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-6405-4-11","article-title":"Predictors of Disease Progression in HIV Infection: A Review","volume":"4","author":"Langford","year":"2007","journal-title":"AIDS Res. Ther."},{"key":"ref_18","unstructured":"Center of Disease Control and Prevention (2024, September 18). Clinical Guidance for PrEP, Available online: https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/index.html."},{"key":"ref_19","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, and Departamento de Doen\u00e7as de Condi\u00e7\u00f5es Cr\u00f4nicas e Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis (2022). Clinical Protocol and Therapeutic Guidelines for Comprehensive Care for People with Sexually Transmitted Infections, Minist\u00e9rio da Sa\u00fade."},{"key":"ref_20","unstructured":"Department of Health and Human Services (2024, September 17). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref_21","unstructured":"(2024, November 28). Guidelines\u2013CPIC. Available online: https:\/\/cpicpgx.org\/guidelines\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2011.355","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing","volume":"91","author":"Martin","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FPC.0000000000000040","article-title":"PharmGKB Summary: Abacavir Pathway","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genom."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/524889","article-title":"Plasmodium Knowlesi: The Fifth Human Malaria Parasite","volume":"46","author":"White","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1475-2875-13-68","article-title":"First Case of a Naturally Acquired Human Infection with Plasmodium Cynomolgi","volume":"13","author":"Ta","year":"2014","journal-title":"Malar. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1038","DOI":"10.1016\/S2214-109X(17)30333-9","article-title":"Outbreak of Human Malaria Caused by Plasmodium Simium in the Atlantic Forest in Rio de Janeiro: A Molecular Epidemiological Investigation","volume":"5","author":"Brasil","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_29","unstructured":"World Health Organization (2023). World Malaria Report 2023, World Health Organization."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrmicro.2016.158","article-title":"Progress in Imaging Methods: Insights Gained into Plasmodium Biology","volume":"15","author":"Burda","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lima-Junior, J.d.C., and Pratt-Riccio, L.R. (2016). Major Histocompatibility Complex and Malaria: Focus on Plasmodium vivax Infection. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00013"},{"key":"ref_32","unstructured":"Minist\u00e9rio da Sa\u00fade, and Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis (2021). Guia de Tratamento Da Mal\u00e1ria No Brasil, Minist\u00e9rio da Sa\u00fade. [2nd ed.]."},{"key":"ref_33","first-page":"taz023","article-title":"Tafenoquine and G6PD: A Primer for Clinicians","volume":"26","author":"Chu","year":"2019","journal-title":"J. Travel Med."},{"key":"ref_34","unstructured":"Pratt, V.M., Scott, S.A., and Pirmohamed, M. (2012). Primaquine Therapy and G6PD and CYP2D6 Genotype, National Center for Biotechnology Information."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00538-19","DOI":"10.1128\/AAC.00538-19","article-title":"CYP2D6 Polymorphisms and the Safety and Gametocytocidal Activity of Single-Dose Primaquine for Plasmodium falciparum","volume":"63","author":"Pett","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cpt.2735","article-title":"Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype","volume":"113","author":"Gammal","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12936-021-03620-6","article-title":"Influence of Cytochrome P450 (CYP) 2C8 Polymorphisms on the Efficacy and Tolerability of Artesunate-amodiaquine Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar","volume":"20","author":"Morris","year":"2021","journal-title":"Malar. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.119.088062","article-title":"Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations","volume":"47","author":"Mutagonda","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12936-024-04930-1","article-title":"Therapeutic Efficacy of Generic Artemether\u2013Lumefantrine in the Treatment of Uncomplicated Malaria in Ghana: Assessing Anti-Malarial Efficacy amidst Pharmacogenetic Variations","volume":"23","author":"Thomford","year":"2024","journal-title":"Malar. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-022-04311-6","article-title":"Association between CYP2D6 Phenotype and Recurrence of Plasmodium vivax Infection in South Korean Patients","volume":"21","author":"Choi","year":"2022","journal-title":"Malar. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e0101423","DOI":"10.1128\/aac.01014-23","article-title":"Cytochrome P450 2D6 Profiles and Anti-Relapse Efficacy of Tafenoquine against Plasmodium vivax in Australian Defence Force Personnel","volume":"67","author":"Dowd","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/infdis\/jiz386","article-title":"Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population","volume":"220","author":"Spring","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Silvino, A.C.R., Costa, G.L., De Ara\u00fajo, F.C.F., Ascher, D.B., Pires, D.E.V., Fontes, C.J.F., Carvalho, L.H., De Brito, C.F.A., and Sousa, T.N. (2016). Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160172"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2217\/pgs-2016-0131","article-title":"The Effect of SNPs in CYP450 in Chloroquine\/Primaquine Plasmodium vivax Malaria Treatment","volume":"17","author":"Sortica","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12936-017-2139-7","article-title":"CYP2D6 Activity and the Risk of Recurrence of Plasmodium Vivax Malaria in the Brazilian Amazon: A Prospective Cohort Study","volume":"17","author":"Brasil","year":"2018","journal-title":"Malar. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e02125-19","DOI":"10.1128\/AAC.02125-19","article-title":"Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax","volume":"64","author":"Almeida","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cardoso, J.L.M., Salazar, Y.E.A.R., Almeida, A.C.G., Barbosa, L.R.A., Silva, E.L., Rodrigues, M.G.A., Rodrigues-Soares, F., Sampaio, V.S., Siqueira, A.M., and Lacerda, M.V.G. (2022). Influence of CYP2D6, CYP3A4 and CYP2C19 Genotypes on Recurrence of Plasmodium vivax. Front. Trop. Dis., 3.","DOI":"10.3389\/fitd.2022.845451"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/jac\/dkae196","article-title":"Monoamine Oxidase-A (MAO-A) Low-Expression Variants and Increased Risk of Plasmodium vivax Malaria Relapses","volume":"79","author":"Rodrigues","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e02056-19","DOI":"10.1128\/AAC.02056-19","article-title":"Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence","volume":"64","author":"Silvino","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Mac\u00eado, M.M., Almeida, A.C.G., Silva, G.S., Oliveira, A.C., Mwangi, V.I., Shuan, A.C., Barbosa, L.R.A., Rodrigues-Soares, F., and Melo, G.C. (2023). Association of CYP2C19, CYP2D6 and CYP3A4 Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients. Pathogens, 12.","DOI":"10.3390\/pathogens12070895"},{"key":"ref_51","unstructured":"World Health Organization (2023). Global Tuberculosis Report 2023, World Health Organization."},{"key":"ref_52","first-page":"1376","article-title":"Diagnostic Standards and Classification of Tuberculosis in Adults and Children","volume":"161","author":"Dunlap","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_53","unstructured":"Center for Disease Control and Prevention (2024, September 19). Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis, Available online: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5801a3.htm?s_cid=mm5801a3_e."},{"key":"ref_54","unstructured":"Center for Disease Control and Prevention (2024, September 19). Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection, Available online: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr4906a1.htm."},{"key":"ref_55","first-page":"108","article-title":"Pharmacogenetics of tuberculosis","volume":"7","author":"Miwa","year":"2024","journal-title":"Acta Biol. Bras."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/ijmy.ijmy_106_24","article-title":"Pharmacogenetic Study of Drugs Affecting Mycobacterium Tuberculosis","volume":"13","author":"Shabani","year":"2024","journal-title":"Int. J. Mycobacteriology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/23744235.2024.2309348","article-title":"Variability in Plasma Rifampicin Concentrations and Role of SLCO1B1, ABCB1, AADAC2 and CES2 Genotypes in Ethiopian Patients with Tuberculosis","volume":"56","author":"Sileshi","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1987","DOI":"10.1002\/mgg3.1987","article-title":"NAT2 and CYP2E1 Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity in Peruvian Patients","volume":"10","author":"Levano","year":"2022","journal-title":"Mol. Genet. Genomic. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ulanova, V., Kivrane, A., Viksna, A., Pahirko, L., Freimane, L., Sadovska, D., Ozere, I., Cirule, A., Sevostjanovs, E., and Grinberga, S. (2024). Effect of NAT2, GSTM1 and CYP2E1 Genetic Polymorphisms on Plasma Concentration of Isoniazid and Its Metabolites in Patients with Tuberculosis, and the Assessment of Exposure-Response Relationships. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1332752"},{"key":"ref_60","first-page":"474","article-title":"Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study","volume":"48","author":"Pourmohamadi","year":"2023","journal-title":"Iran. J. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/infdis\/jiac024","article-title":"Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa","volume":"226","author":"Haas","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41397-022-00272-w","article-title":"A Systematic Review on the Cost Effectiveness of Pharmacogenomics in Developing Countries: Implementation Challenges","volume":"22","author":"Sukri","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1093\/cid\/ciz1212","article-title":"Cost-Effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis","volume":"71","author":"Rens","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/cpt.2754","article-title":"Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review","volume":"112","author":"Morris","year":"2022","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/1\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:23:15Z","timestamp":1759918995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/1\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,5]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["genes16010054"],"URL":"https:\/\/doi.org\/10.3390\/genes16010054","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2025,1,5]]}}}